Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatran
Objective: To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent. Methods: A literature search was conduc...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , |
| التنسيق: | article |
| منشور في: |
2015
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/6127 http://dx.doi.org/10.1177/0897190015615248 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://journals.sagepub.com/doi/pdf/10.1177/0897190015615248 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513478564249600 |
|---|---|
| author | Kuyumjian, Yara |
| author2 | Miyares, Marta A. Eaves, Shannon |
| author2_role | author author |
| author_facet | Kuyumjian, Yara Miyares, Marta A. Eaves, Shannon |
| author_role | author |
| dc.creator.none.fl_str_mv | Kuyumjian, Yara Miyares, Marta A. Eaves, Shannon |
| dc.date.none.fl_str_mv | 2015 2017-09-05T08:48:33Z 2017-09-05T08:48:33Z 2017-09-05 |
| dc.identifier.none.fl_str_mv | 1531-1937 http://hdl.handle.net/10725/6127 http://dx.doi.org/10.1177/0897190015615248 Miyares, M. A., Kuyumjian, Y., Eaves, S., & Dollard, E. (2015). Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran. Journal of pharmacy practice, 28(6), 548-554. http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://journals.sagepub.com/doi/pdf/10.1177/0897190015615248 |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | Journal of Pharmacy Practice |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatran |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | Objective: To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent. Methods: A literature search was conducted consisting of a PubMed database using the MeSH term idarucizumab and the key word dabigatran antidote. Studies evaluating the pharmacology, pharmacokinetics, safety, and efficacy of idarucizumab for the reversal of the anticoagulant activity of dabigatran were included. Results: Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran. Studies evaluating reversal of dabigatran-induced anticoagulation have demonstrated immediate, complete, and sustained effects with idarucizumab. Idarucizumab did not overcorrect thrombin generation. Additionally, evaluations have shown that dabigatran can be safely reinitiated 24 hours after the administration of idarucizumab. The United States Food and Drug Administration granted priority review for the biologic license application and accelerated approval for idarucizumab. Conclusion: Idarucizumab represents an encouraging development in the reversal of dabigatran. Its novel mechanism of action, pharmacokinetics, tolerability, and lack of thrombotic events contribute positively to its use in patients who experience bleeding or for those who require emergent surgery or procedures. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_c08a8e3d7a7e33ee9fc3012d37518b65 |
| identifier_str_mv | 1531-1937 Miyares, M. A., Kuyumjian, Y., Eaves, S., & Dollard, E. (2015). Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran. Journal of pharmacy practice, 28(6), 548-554. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/6127 |
| publishDate | 2015 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatranKuyumjian, YaraMiyares, Marta A.Eaves, ShannonObjective: To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this agent. Methods: A literature search was conducted consisting of a PubMed database using the MeSH term idarucizumab and the key word dabigatran antidote. Studies evaluating the pharmacology, pharmacokinetics, safety, and efficacy of idarucizumab for the reversal of the anticoagulant activity of dabigatran were included. Results: Idarucizumab represents a novel treatment option as it is the only humanized, monoclonal antibody fragment that specifically binds to dabigatran. Studies evaluating reversal of dabigatran-induced anticoagulation have demonstrated immediate, complete, and sustained effects with idarucizumab. Idarucizumab did not overcorrect thrombin generation. Additionally, evaluations have shown that dabigatran can be safely reinitiated 24 hours after the administration of idarucizumab. The United States Food and Drug Administration granted priority review for the biologic license application and accelerated approval for idarucizumab. Conclusion: Idarucizumab represents an encouraging development in the reversal of dabigatran. Its novel mechanism of action, pharmacokinetics, tolerability, and lack of thrombotic events contribute positively to its use in patients who experience bleeding or for those who require emergent surgery or procedures.PublishedN/A2017-09-05T08:48:33Z2017-09-05T08:48:33Z20152017-09-05Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1531-1937http://hdl.handle.net/10725/6127http://dx.doi.org/10.1177/0897190015615248Miyares, M. A., Kuyumjian, Y., Eaves, S., & Dollard, E. (2015). Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran. Journal of pharmacy practice, 28(6), 548-554.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttp://journals.sagepub.com/doi/pdf/10.1177/0897190015615248enJournal of Pharmacy Practiceinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/61272021-03-19T10:00:52Z |
| spellingShingle | Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatran Kuyumjian, Yara |
| status_str | publishedVersion |
| title | Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatran |
| title_full | Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatran |
| title_fullStr | Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatran |
| title_full_unstemmed | Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatran |
| title_short | Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatran |
| title_sort | Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatran |
| url | http://hdl.handle.net/10725/6127 http://dx.doi.org/10.1177/0897190015615248 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://journals.sagepub.com/doi/pdf/10.1177/0897190015615248 |